NASDAQ:ELEV Elevation Oncology - ELEV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.02 -0.02 (-1.92%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.01▼$1.0450-Day Range$0.75▼$1.1652-Week Range$0.72▼$5.20Volume11,675 shsAverage Volume171,481 shsMarket Capitalization$23.77 millionP/E RatioN/ADividend YieldN/APrice Target$5.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Elevation Oncology MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside471.9% Upside$5.83 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.02Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.97) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector150th out of 1,055 stocksBiological Products, Except Diagnostic Industry26th out of 170 stocks 3.1 Analyst's Opinion Consensus RatingElevation Oncology has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.83, Elevation Oncology has a forecasted upside of 471.9% from its current price of $1.02.Amount of Analyst CoverageElevation Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.22% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevation Oncology has recently decreased by 29.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELEV. Previous Next 3.3 News and Social Media Coverage News SentimentElevation Oncology has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Elevation Oncology this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Elevation Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.01% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Elevation Oncology are expected to grow in the coming year, from ($3.97) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Elevation Oncology (NASDAQ:ELEV) StockElevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.Read More Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ELEV Stock News HeadlinesJanuary 25, 2023 | marketbeat.comHow Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (ELEV)Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.January 27, 2023 | americanbankingnews.comWedbush Analysts Raise Earnings Estimates for Elevation Oncology, Inc. (NASDAQ:ELEV)January 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 26, 2023 | seekingalpha.comELEV Elevation Oncology, Inc.January 26, 2023 | americanbankingnews.comBrokers Offer Predictions for Elevation Oncology, Inc.'s FY2027 Earnings (NASDAQ:ELEV)January 24, 2023 | americanbankingnews.comElevation Oncology, Inc. (NASDAQ:ELEV) Short Interest UpdateJanuary 9, 2023 | finance.yahoo.comElevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2023 | msn.comElevation Oncology CEO resigns as part of company prioritization effortJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 6, 2023 | finance.yahoo.comElevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO TransitionNovember 30, 2022 | finance.yahoo.comElevation Oncology to Participate at the JMP Securities Hematology and Oncology SummitNovember 3, 2022 | finance.yahoo.comElevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressAugust 4, 2022 | finance.yahoo.comMerrimack Reports Second Quarter 2022 Financial ResultsAugust 3, 2022 | finance.yahoo.comElevation Oncology to Participate at the Wedbush PacGrow Healthcare ConferenceJuly 30, 2022 | morningstar.comElevation Oncology Inc Stock NewsJuly 12, 2022 | uk.investing.comElevation Oncology Inc (ELEV)July 12, 2022 | uk.investing.comShort Volatility Alert: Elevation Oncology, Inc.May 27, 2022 | uk.investing.comWhy Elevation Oncology Stock Is RisingMay 27, 2022 | barrons.comElevation Oncology Inc.May 27, 2022 | morningstar.comElevation Oncology Gets Fast Track Designation for Seribantumab to Treat Tumors Harboring NRG1 Gene FusionsMay 26, 2022 | finance.yahoo.comElevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022May 26, 2022 | finance.yahoo.comEstimating The Intrinsic Value Of Elevation Oncology, Inc. (NASDAQ:ELEV)May 25, 2022 | msn.comElevation Oncology Shares Gain On FDA Fast Track Designation For Seribantumab In Tumor-Agnostic SettingsMay 25, 2022 | seekingalpha.comElevation gets FDA fast track status for seribantumab to treat gene-specific solid tumorsMay 25, 2022 | finance.yahoo.comElevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene FusionsMay 5, 2022 | apnews.comMerrimack Reports First Quarter 2022 Financial ResultsMay 5, 2022 | finance.yahoo.comElevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company ProgressSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ELEV Company Calendar Last Earnings11/03/2022Today1/28/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.83 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+471.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-78.52% Return on Assets-66.01% Debt Debt-to-Equity Ratio0.44 Current Ratio7.29 Quick Ratio7.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.06 per share Price / Book0.17Miscellaneous Outstanding Shares23,300,000Free Float19,340,000Market Cap$23.77 million OptionableNot Optionable Beta0.30 Key ExecutivesDr. Shawn M. Leland Pharm.D. (Age 38)R.Ph., Founder, Pres, CEO & Director Comp: $737.97kMr. Joseph J. Ferra Jr. (Age 46)Chief Financial Officer Comp: $391.52kMs. Valerie Malyvanh Jansen M.D. (Age 44)Ph.D., Chief Medical Officer Comp: $476.7kMs. Tammy Furlong CPAP.M.P., VP of Fin. & Accounting and Sec.Dr. David Dornan Ph.D. (Age 44)Chief Scientific Officer Candice MasseSr. Director of Corp. Communications & Investor RelationsMr. Robert C. YangVP of Legal AffairsMr. Brian SullivanVP of Corp. Devel.Mr. Ryan BloomerHead of CMCMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXSQZ BiotechnologiesNYSE:SQZAcorda TherapeuticsNASDAQ:ACORRubius TherapeuticsNASDAQ:RUBYMicrobot MedicalNASDAQ:MBOTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 67,829 shares on 11/15/2022Ownership: 1.429%Cormorant Asset Management LPSold 31,136 shares on 11/14/2022Ownership: 8.377%Renaissance Technologies LLCBought 30,257 shares on 11/14/2022Ownership: 1.239%Annandale Capital LLCBought 30,000 shares on 11/14/2022Ownership: 0.129%Global Strategic Fund I VenbioSold 702,737 sharesTotal: $2.90 M ($4.12/share)View All Insider TransactionsView All Institutional Transactions ELEV Stock - Frequently Asked Questions Should I buy or sell Elevation Oncology stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ELEV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELEV, but not buy additional shares or sell existing shares. View ELEV analyst ratings or view top-rated stocks. What is Elevation Oncology's stock price forecast for 2023? 4 analysts have issued 1-year price targets for Elevation Oncology's stock. Their ELEV share price forecasts range from $2.00 to $8.00. On average, they anticipate the company's stock price to reach $5.83 in the next twelve months. This suggests a possible upside of 471.9% from the stock's current price. View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts. How have ELEV shares performed in 2023? Elevation Oncology's stock was trading at $0.95 at the beginning of the year. Since then, ELEV stock has increased by 7.4% and is now trading at $1.02. View the best growth stocks for 2023 here. Are investors shorting Elevation Oncology? Elevation Oncology saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 33,700 shares, a decrease of 29.4% from the December 31st total of 47,700 shares. Based on an average daily volume of 81,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are sold short. View Elevation Oncology's Short Interest. When is Elevation Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our ELEV earnings forecast. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) posted its earnings results on Thursday, November, 3rd. The company reported ($1.67) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.55. When did Elevation Oncology IPO? (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at a price of $15.00-$17.00 per share. What is Elevation Oncology's stock symbol? Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV." How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Elevation Oncology's stock price today? One share of ELEV stock can currently be purchased for approximately $1.02. How much money does Elevation Oncology make? Elevation Oncology (NASDAQ:ELEV) has a market capitalization of $23.77 million. The company earns $-32,040,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. How can I contact Elevation Oncology? The official website for the company is www.elevationoncology.com. The company can be reached via phone at 716-371-1125 or via email at ir@elevationoncology.com. This page (NASDAQ:ELEV) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.